Standard Biotools Inc. (LAB): Net Income
-$74.90M
Year ended 2025-12-31
$84.91M
Trailing 12 months to 2026-06-30
| Period ended | Net Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$74.90M | n/m | 2026-03-16, From 2025-01-01 |
| 2024-12-31 | -$138.88M | n/m | 2026-03-16, From 2024-01-01 |
| 2023-12-31 | -$74.66M | n/m | 2026-03-16, From 2023-01-01 |
| 2022-12-31 | -$190.10M | n/m | 2025-03-11, From 2022-01-01 |
| 2021-12-31 | -$59.24M | n/m | 2023-03-14, From 2021-01-01 |
| 2020-12-31 | -$53.02M | n/m | 2022-03-08, From 2020-01-01 |
| 2019-12-31 | -$64.79M | n/m | 2022-03-08, From 2019-01-01 |
| 2018-12-31 | -$59.01M | n/m | 2021-02-25, From 2018-01-01 |
| 2017-12-31 | -$60.53M | n/m | 2020-02-27, From 2017-01-01 |
| 2016-12-31 | -$75.98M | n/m | 2019-03-18, From 2016-01-01 |
| 2015-12-31 | -$53.31M | n/m | 2018-03-08, From 2015-01-01 |
| 2014-12-31 | -$52.83M | n/m | 2017-03-03, From 2014-01-01 |
| 2013-12-31 | -$16.53M | n/m | 2016-02-29, From 2013-01-01 |
| 2012-12-31 | -$19.02M | n/m | 2015-02-26, From 2012-01-01 |
| 2011-12-31 | -$22.47M | n/m | 2014-03-12, From 2011-01-01 |
| 2010-12-31 | -$16.90M | n/m | 2013-03-12, From 2010-01-01 |
| 2009-12-31 | -$19.13M | n/a | 2012-03-26, From 2009-01-01 |
Net Income at similar companies
| Company | Year ended | Net Income | Change YoY |
|---|---|---|---|
| Standard Biotools Inc. (LAB) | 2025-12-31 | -$74.90M | n/m |
| ARS Pharmaceuticals, Inc. (SPRY) | 2025-12-31 | -$171.30M | n/m |
| Nurix Therapeutics, Inc. (NRIX) | 2025-11-30 | -$264.46M | n/m |
| Cytokinetics Inc (CYTK) | 2025-12-31 | -$784.96M | n/m |
| Arcturus Therapeutics Holdings Inc. (ARCT) | 2025-12-31 | -$65.78M | n/m |
| ADC Therapeutics SA (ADCT) | 2025-12-31 | -$142.62M | n/m |
| Eton Pharmaceuticals, Inc. (ETON) | 2025-12-31 | -$4.60M | n/m |
| Siga Technologies Inc (SIGA) | 2025-12-31 | $23.28M | -60.7% |
| CytomX Therapeutics, Inc. (CTMX) | 2025-12-31 | -$17.37M | n/m |
Compare LAB, SPRY, NRIX, CYTK side by side · Screen every company in Pharmaceutical Preparations ↗